Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA).

被引：0

作者：

Makawita, Shalini

Gibbs, Jerry M.

McFadden, Dustin R.

Porter, Caroline

Shaw, Amanda Rosewell

Robertson, Catherine

Woods, Mae Louise

Wang, Tao

Grilley, Bambi J.

Heslop, Helen E.

Brenner, Malcolm K.

Suzuki, Masataka

机构：

[1] Baylor Coll Med, Houston, TX USA

[2] Houston Methodist Hosp, Houston, TX USA

[3] Baylor Coll Med, Cell & Gene Therapy, Houston, TX USA

[4] Texas Childrens Hosp, Houston, TX USA

[5] Baylor Coll Med, Div Diabet Endocrinol & Metab, Houston, TX USA

[6] Baylor Coll Med, Div Pediat, Houston, TX USA

[7] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA

[8] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS2679

引用

页数：1

共 50 条

[21] A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
Richards, Donald A.
Braiteh, Fadi S.
Anthony, Stephen Patrick
Edenfield, Jeff
Hellerstedt, Beth A.
Raju, Robert N.
Conkling, Paul
Smith, David A.
Becerra, Carlos
Cohn, Allen Lee
Denlinger, Crystal Shereen
Garbo, Lawrence E.
Wu, Hillary H.
Garcia, Agustin
McDonagh, Charlotte
Frye, Sasha
Agresta, Samuel V.
Moyo, Victor M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] Breast Cancer: Specific Aspects of the Therapy of small HER2-positive Tumors
Bartsch, R.
Bago-Horvath, Z.
Kauer-Domer, D.
Berghoff, A.
Dubsky, P.
TUMORBOARD, 2012, 1 (01): : 21 - 26
[23] Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer
Matusz-Fisher, Ashley
Tan, Antoinette R.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (03) : 385 - 395
[24] Preclinical characterization of allogeneic V.9Vd2 HER2-TAC T cells for the treatment of HER2-positive solid tumors
Prosser, Suzanna L.
Xu, Stacey X.
Wang, Ling
Randhawa, Ritu R.
Pirati, Sailaja
Ravensbergen, Laura
Yoo, Seungmi
Jung, Miyoung
Gheorghiu, Laurentia
Gomez, Angel
Sandhu, Gurleen
Ayers, Chris
Rill, Donna
Helsen, Christopher W.
Bader, Andreas G.
CANCER RESEARCH, 2023, 83 (07)
[25] Studies on the efficacy of pyrotinib in the treatment of HER-2 positive advanced solid tumors.
Fan, Shaoshuang
Jiang, Da
Lv, Yalei
Cui, Yanzhi
Kong, Yan
Dong, Qian
Huang, Fang
Zhang, Xue
Wang, Long
Zhou, Xinliang
Jin, Hui
Li, Ying
Hou, Ran
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Use of HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma
Schneider, Julia R.
Kwan, Kevin
Boockvar, John A.
NEUROSURGERY, 2017, 81 (05) : N42 - N43
[27] Biomarkers to predict sensitivity to HER2-targeting treatment in HER2-positive advanced gastric cancer.
Kim, Tae Yong
Ock, Chan-Young
Oh, Do-Youn
Lee, Kyung-Hun
Han, Sae-Won
Im, Seock-Ah
Kim, Tae-You
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[28] Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
Hurvitz, Sara A.
Kakkar, Reva
BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 35 - 51
[29] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
Paridaens, R., Sr.
Wildiers, H.
Dalenc, F.
Rixe, O.
Cadic, V.
Pinel, M.
Roche, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[30] Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
Kaufman, Bella
Stein, Steven
Casey, Michelle A.
Newstat, Beth O.
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 61 - 65

← 1 2 3 4 5 →